Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
52.34
-0.29 (-0.55%)
Sep 27, 2024, 4:00 PM EDT - Market closed
Cytokinetics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 81.79, with a low estimate of 60 and a high estimate of 106. The average target predicts an increase of 56.27% from the current stock price of 52.34.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 | 5 | 5 |
| Buy | 6 | 7 | 7 | 7 | 7 | 6 |
| Hold | 2 | 3 | 3 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 16 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +71.95% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +71.95% | Sep 9, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $65 → $71 | Buy | Maintains | $65 → $71 | +35.65% | Sep 5, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $78 | Buy | Reiterates | $78 | +49.03% | Sep 4, 2024 |
Financial Forecast
Revenue This Year
7.48M
from 7.53M
Decreased by -0.61%
Revenue Next Year
69.39M
from 7.48M
Increased by 827.22%
EPS This Year
-5.29
from -5.45
EPS Next Year
-5.00
from -5.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 44.2M | 237.2M | 578.5M | ||
| Avg | 7.5M | 69.4M | 358.0M | ||
| Low | 1.1M | 15.5M | 200.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 487.2% | 3,069.4% | 733.6% | ||
| Avg | -0.6% | 827.2% | 415.9% | ||
| Low | -85.9% | 107.3% | 188.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.82 | -3.68 | -1.27 | ||
| Avg | -5.29 | -5.00 | -3.35 | ||
| Low | -5.49 | -6.58 | -5.68 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.